Dabigatran
- Generic Name
- Dabigatran
- Brand Names
- Dabigatran Etexilate Leon Farma, Dabigatran Etexilate Accord, Pradaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N7O3
- CAS Number
- 211914-51-1
- Unique Ingredient Identifier
- I0VM4M70GC
- Background
Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.
- Associated Conditions
- -
- Associated Therapies
- -
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
- Conditions
- Interventions
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2018-06-07
- Lead Sponsor
- Martini Hospital Groningen
- Target Recruit Count
- 148
- Registration Number
- NCT01431456
- Locations
- 🇳🇱
Martini Ziekenhuis, Groningen, Netherlands
Safety Study of Dabigatran in CADASIL
- First Posted Date
- 2011-05-27
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- S. Andrea Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01361763
- Locations
- 🇮🇹
Emergency Department Stroke Unit, Umberto I Hospital, Rome, Italy
🇮🇹NESMOS Department St. Andrea Hospital, Rome, Italy
Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2015-02-05
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Target Recruit Count
- 46
- Registration Number
- NCT01352702
- Locations
- 🇩🇪
Deutsches Herzzentrum Muenchen, Munich, Germany
Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation
- First Posted Date
- 2011-04-21
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Target Recruit Count
- 70
- Registration Number
- NCT01339819
- Locations
- 🇩🇪
Deutsches Herzzentrum Muenchen, Munich, Germany
Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 167
- Registration Number
- NCT01153698
- Locations
- 🇦🇹
1160.118.43007 Boehringer Ingelheim Investigational Site, Wien, Austria
🇦🇹1160.118.43004 Boehringer Ingelheim Investigational Site, Braunau, Austria
🇦🇹1160.118.43016 Boehringer Ingelheim Investigational Site, Stolzalpe, Austria
Secondary Prevention of Venous Thrombo Embolism (VTE).
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2867
- Registration Number
- NCT00329238
- Locations
- 🇺🇸
1160.47.01030 Boehringer Ingelheim Investigational Site, Grand Forks, North Dakota, United States
🇨🇦1160.47.02019 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
🇲🇽1160.47.52030 Boehringer Ingelheim Investigational Site, Guadalajara, Jal., Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.